BRAF and neoplasm: Our hypothesis led to the identification of DUSP6 as a potential synthetic lethal target in melanoma with BRAF V600E mutation and high expression of DUSP6, suggesting that, in certain scenarios, this tumor suppressor may serve as drug target.